Cancer Detection and Cancer Characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) - Section Rotterdam. A Comparison of Two Rounds of Screening

European Urology

Volumn 52, Issue 1, 2007, Pages 89-97

  Postma, Renske ^a   Schröder, Fritz H ^a   van Leenders, Geert J L H ^a   Hoedemaeker, Robert F ^a   Vis, Andre N ^a   Roobol, Monique J ^a   van der Kwast, Theodorus H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Prognostic factors; Prostate cancer; PSA progression; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TUMOR BIOPSY; TUMOR VOLUME; WATCHFUL WAITING;

AGED; BIOPSY; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; NETHERLANDS; PREVALENCE; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 34249052873     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.01.030     Document Type: Article

References (27)

1. de Koning H.J., Liem M.K., Baan C.A., et al. ERSPC. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 98 (2002) 268-273
2. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
3. Hankey B.F., Feuer E.J., Clegg L.X., et al. Cancer surveillance series: interpreting trends in prostate cancer, part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91 (1999) 1017-1024
4. Spapen S.J., Damhuis R.A., and Kirkels W.J. Trends in the curative treatment of localized prostate cancer after the introduction of prostate-specific antigen: data from the Rotterdam Cancer Registry. BJU Int 85 (2000) 474-480
5. Hoedemaeker R.F., van der Kwast T.H., Boer R., et al. Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst 93 (2001) 1153-1158
6. Roobol M.J., Kranse R., De Koning H.J., et al. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: Results of second screening round of ERSPC (Rotterdam). Urology 63 (2004) 309-315
7. Raaijmakers R., Blijenberg B.G., Finlay J.A., et al. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3. 9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol 171 (2004) 2245-2249
8. Hoedemaeker R.F., Ruizeveld de Winter J.A., Van der Kaa C.A., et al. Processing radical prostatectomy specimens: a comprehensive and standardized protocol. J Urol Pathol 9 (1998) 211-222
9. Schroder F.H., Hermanek P., Denis L., et al. The TNM classification of prostate cancer. Prostate Suppl 4 (1992) 129-138
10. Hoedemaeker R.F., Rietbergen J.B., Kranse R., et al. Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer. World J Urol 15 (1997) 339-345
11. van der Cruijsen-Koeter I.W., van der Kwast T.H., and Schroder F.H. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 95 (2003) 1462-1466
12. Tabar L., Faberberg G., Fay N.E., and Holmberg L. What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer 55 (1987) 547-551
13. Schroder FH, Roobol MJ, editors. European Randomized Study of Screening for Prostate Cancer (ERSPC): rationale, structure and preliminary results 1994-2003. BJU Int 2003;92(suppl 2).
14. Roobol M.J., and Schroder F.H. European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int 92 suppl 2 (2003) 117-122
15. Makinen T., Tammela T.L., Stenman U.H., et al. Second round results of the Finnish population-based prostate cancer screening trial. Clin Cancer Res 10 (2004) 2231-2236
16. Hugosson J., Aus G., Lilja H., et al. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 100 (2004) 1397-1405
17. Schroder F.H., Raaijmakers R., Postma R., et al. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. J Urol 174 (2005) 489-494
18. Kattan M.W., Eastham J.A., Wheeler T.M., et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170 (2003) 1792-1797
19. Epstein J.I., Chan D.W., Sokoll L.J., et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160 (1998) 2407-2411
20. Krumholtz J.S., Carvalhal G.F., Ramos C.G., et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 60 (2002) 469-473 discussion 473-4
21. Augustin H., Hammerer P.G., Graefen M., et al. Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. Eur Urol 43 (2003) 455-460
22. Sokoloff M.H., Yang X.J., Fumo M., et al. Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of <4.0 ng/mL. BJU Int 93 (2004) 499-502
23. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868-878
24. Steyerberg E.W., Roobol M.J., Kattan M.W., et al. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 177 (2007) 107-112 discussion 112
25. Roehl K.A., Han M., Ramos C.G., et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172 (2004) 910-914
26. Hull G.W., Rabbani F., Abbas F., et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167 2 pt 1 (2002) 528-534
27. van der Cruijsen-Koeter I.W., Roobol M.J., Wildhagen M.F., et al. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam. Urology 68 (2006) 615-620